Skip to main content

Table 3 Comparison of laboratory results before and after the treatment between groups (Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)

From: Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study

  Compare groups Mean difference SE p 95% CI
CRP Group 2–Group 3 37.0 9.9 0.001 13.3–60.6
Group 1–Group 2 13.9 12.5 0.512  − 15.6–43.7
Group 1–Group 3 50.9 10.2  < 0.001 26.5–75.2
Lymphocyte Group 2–Group 3 16.8 166.3 0.994  − 425.0–391.4
Group 2–Group 1 253.0 129.8 0.131  − 56.8–562.7
Group 3–Group 1 236.2 152.5 0.286  − 143.7–616.1
D-Dimer Group 2–Group 3 0.41 0.72 0.837  − 1.34–2.16
Group 2–Group 1 0.83 0.58 0.333  − 0.58–2.25
Group 3–Group 1 0.42 0.88 0.881  − 1.68–2.53
AST Group 2–Group 3 20.1 7.3 0.022 2.42–37.7
Group 1–Group 2 2.4 8.2 0.952  − 17.1–22.0
Group 1–Group 3 22.5 5.5  < 0.001 9.4–35.6
ALT Group 2–Group 3 10.2 8.3 0.441  − 9.8–30.3
Group 1–Group 2 3.9 8.3 0.887  − 16.0–23.8
Group 1–Group 3 14.1 6.4 0.083  − 1.5–29.8
Ferritin Group 2–Group 3 240.2 90.0 0.030 20.2–460.2
Group 1–Group 2 119.1 151.3 0.712  − 244.7–482.8
Group 1–Group 3 359.3 137.5 0.032 25.6–693.1
Cr Group 3–Group 2 2.39 1.17 0.138  − 0.67–5.44
Group 1–Group 2 0.25 0.39 0.804  − 0.69–1.18
Group 3–Group 1 2.15 1.22 0.212  − 0.98–5.27
  1. Statistically significant values are presented in bold. Tukey's test and Games Howell tests were preferred as posthoc tests
  2. ALT alanine aminotransferase; AST aspartate aminotransferases; CRP c-reactive protein; Cr Creatinin